ClinicalTrials.gg
CompletedNCT06952634Updated May 12, 2026

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

A Phase 1 interventional study of envudeucitinib in Hepatic Impairment, sponsored by Alumis Inc. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Alumis Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria for All Participants:

  • between 18.0 and 40.0 kg/m2

Key Inclusion Criteria for Participants with Hepatic Impairment:

  • Diagnosis of chronic (> 6 months), stable hepatic impairment with no changes within 30 days prior to dosing, as determined by medical history

Key Exclusion Criteria for All Participants:

  • Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg), or resting pulse rate \< 45 or > 100 bpm. Measurements may be repeated once in order to determine eligibility

Key Exclusion Criteria for Healthy Volunteer:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
  • Positive hepatitis panel and/or positive test.

Key Exclusion Criteria for Participants with Hepatic Impairment:

  • History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.
  • History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.
  • Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.
  • > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Healthy Volunteer

    Up to 24 healthy volunteer participants will receive a single dose of ESK-001

    Drug: envudeucitinib

  • Experimental
    Mild Hepatic Impairment

    8 participants with mild hepatic impairment will receive a single dose of ESK-001

    Drug: envudeucitinib

  • Experimental
    Moderate Hepatic Impairment

    8 participants with moderate hepatic impairment will receive a single dose of ESK-001

    Drug: envudeucitinib

  • Experimental
    Severe Hepatic Impairment

    8 participants with severe hepatic impairment will receive a single dose of ESK-001

    Drug: envudeucitinib

Interventions

  • Single oral dose of ESK-001 in participants from all cohorts

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: 48 hours

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]

    Time frame: 48 hours

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: 48 hours

Secondary outcomes

  1. Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation

    Time frame: 48 hours

  2. Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations

    Time frame: 48 hours

07

Study locations

4 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33104, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Alliance for Multispecialty Research
    Knoxville, Tennessee 37920, United States
08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage pharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Mar 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 1, 2025
StartActual
Apr 29, 2025
Primary completionActual
Mar 24, 2026
CompletionActual
Mar 24, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952634
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Apr 29, 2025
Primary completion
Mar 24, 2026
Completion
Mar 24, 2026
Last update
May 12, 2026

Study contacts

Jorn Drappa, Medical Director
study director · Alumis Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion